

The fantastic voyage of solid lipid nanoparticles from the lung to the brain: non-invasive tomographic imaging as a feasible refinement process

G. Terribile,¹ S. Di Girolamo,^{1,2}
E. Donzelli,³ F. Re,⁴ P. Gasco,⁵
G. Sancini⁴

¹School of Medicine and Surgery,
University of Milano-Bicocca, Monza;

²PhD Program in Neuroscience,
University of Milano-Bicocca;

³Experimental Neurology Group, School
of Medicine and Surgery, University of
Milano-Bicocca, Monza; ⁴Nanomedicine
Center, Neuroscience Center, School of
Medicine and Surgery, University of
Milano-Bicocca, Monza; ⁵Nanovector
S.r.l., Torino, Italy

Solid Lipid Nanoparticles (SLN) are colloidal drug delivery systems characterized by higher entrapment efficiency, good scalability of the preparation process and increased sustained release of the payload. Surface functionalization of SLN with lig-

ands to achieve a site specific targeting makes them attractive to overcome the limited Blood-Brain Barrier (BBB) penetration of therapeutic compounds. SLN are prepared for brain targeting by exploiting the adaptability of warm microemulsion process for the covalent surface modification with an Apolipoprotein E-derived peptide (SLN-mApoE). Furthermore, the influence of the administration route on SLN-mApoE brain bioavailability is here evaluated by means of Fluorescence Molecular Tomography, an advanced optical imaging technology that uses the Near-Infrared Spectrum (NIR) (600-900 nm) for non-invasive *in vivo* imaging and 3D quantification of the fluorescent probes. Fluorescent labelled SLN-mApoE are able to cross intact a BBB *in vitro* model. The pulmonary administration of SLN-mApoE is related to a higher confinement in the brain of Balb/c mice compared to the intravenous and intraperitoneal administration routes, without inducing any acute inflammatory reaction in the lungs. These results promote the pulmonary administration of brain-targeted SLN as a feasible strategy for improving brain delivery of therapeutics as well as the FMT's ability of quantitative assessment *in vivo*-bio-distribution studies.

Correspondence: G. Sancini
E-mail: giulio.sancini@unimib.it

Conference presentation: this paper was presented at the Fourth Centro 3R Annual Meeting - The role of 3Rs in the age of One Health: where we are and where we're going - 13-15 September 2023, Università degli Studi Milano-Bicocca.

©Copyright: the Author(s), 2023
Licensee PAGEPress, Italy
Biomedical Science and Engineering 2023; 4:224
doi:10.4081/bse.2023.224

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.